Correction to: A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

Oncologist. 2024 Mar 18:oyae053. doi: 10.1093/oncolo/oyae053. Online ahead of print.NO ABSTRACTPMID:38498842 | DOI:10.1093/oncolo/oyae053
Source: The Oncologist - Category: Cancer & Oncology Source Type: research